Research progress of terlipressin in the treatment of cirrhotic ascites-related complications
10.3760/cma.j.issn.1007-3418.2019.12.005
- VernacularTitle: 特利加压素治疗肝硬化腹水相关并发症的研究进展
- Author:
Chenghai LIU
1
;
Feng XING
;
Jing WANG
Author Information
1. Institute of Liver Diseases, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
- Publication Type:Journal Article
- Keywords:
Liver cirrhosis;
Ascites;
Complication;
Terlipressin;
Splanchnic vasodilatation
- From:
Chinese Journal of Hepatology
2019;27(12):929-932
- CountryChina
- Language:Chinese
-
Abstract:
Ascites is the most common clinical symptom in the decompensated stage of patients with liver cirrhosis, and its co-existence in complex conditions, such as refractory ascites, hyponatremia, hepatorenal syndrome and other complications may harm seriously. Splanchnic vasodilation is the key pathological link of cirrhotic ascites-related complications and the treatment of this link can help to eliminate the symptoms of ascites and prevent the further deterioration of decompensated cirrhosis. This paper summaries the pharmacological basis, clinical evidence and application characteristics of a vasocative drugs-terlipressin in the treatment of cirrhotic ascites-related complications, and further analyzes the problems existing in the current research, then proposes a prospect.
